Table 2

 Uveitis flares before and during each kind of anti-tumour necrosis factor (TNF) treatment (n = 46 patients), in patients with spondylarthropathy: comparison between uveitis flares during the treatment with those during treatment with anti-TNF antibody and soluble TNF receptor

Anti-TNF (n =  patients)Period before anti-TNF treatmentPeriod during anti-TNF treatmentp Value*
Duration of period (years)Mean (SD)Number of uveitis flares/patient Mean (SD)Number of uveitis flares/100 patient-years Mean (SD)Treatment period (years)Mean (SD)Number of uveitis flares/patient Mean (SD)Number of uveitis flares/100 patient-years Mean (SD)
TNF, tumour necrosis factor.
*p Value comparing the number of uveitis flares/100 patient-years before and during the treatment. Each patient is his or her own control.
All anti-TNF n = 4615.2 (10.2)6.3 (9.7)51.8 (65.0)1.2 (1.1)0.2 (1.0)21.4 (74.9)0.03
Soluble TNF receptor (etanercept) n = 1311.5 (10.4)3.6 (4.1)54.6 (78.2)1.2 (1.1)0.5 (0.8)58.5 (121.9)0.92
Anti-TNF antibodies (adalimumab and infliximab) n = 3316.7 (9.8)7.3 (11.1)50.6 (61.0)1.2 (1.1)0.1 (1.0)6.8 (39.3)0.001
Infliximab n = 2516.8 (10.4)7.3 (12.1)47.4 (58.9)1.4 (1.3)0.2 (1.2)9.0 (45.2)0.008
Adalimumab n = 816.2 (8.7)7.2 (7.8)60.5 (70.4)0.6 (0.2)000.04